83 GHP Healthcare & Pharma Awards 2023 Swiss medtech company, Implantica Trading AG (Implantica) is dedicated to developing and bringing to market innovative, smart medical implants. By leveraging state-ofthe-art technology, the company plans to revolutionise healthcare by alleviating unmet medical needs. We chat with Implantica’s Vice President of Marketing & Advocacy, Juanita Eberhart to find out more about the company’s products and its vision for the future. Smart medical implants represent a transformative leap in the field of healthcare. The designs of these remarkable devices integrate with the human body. By using cutting-edge technologies such as sensors, microprocessors, and wireless communication, implants are able to monitor, diagnose, and even treat a wide range of medical conditions. Probably the most well-known medical implant is the pacemaker which monitors and regulates the rhythm of the heart. As technology evolves, the possibilities for smart medical implants become boundless. Smart implants can provide real-time data, targeted drug release, and even help to restore lost sensory function. As a result, the risks associated with treatment are reduced, improving the quality of care and the patient’s well-being. Leading the way in the development of new smart implants is Zug-based company, Implantica. Founded over 10 years ago, the company is the brainchild of renowned surgeon and inventor, Peter Forsell. Implantica is striving to become a world leader in the field of smart medical implants thereby improving healthcare. Juanita tells us, “It’s our aim to be at the forefront of the fast-growing e-health market. We want to develop new, improved healthcare devices, provide effective care for serious health conditions, increase patients’ quality of life worldwide, and save costs for society.” After a significant period of research and development, Implantica received CE-Mark approval for its first medical device in 2018. Known as RefluxStop™, the ingenious device is a non-active implant used in the treatment of chronic acid reflux – a disease that impacts the daily lives of over 400 million people. The device, placed on the upper part of the stomach by means of keyhole surgery, is now available in the UK, Germany, Spain, and Italy. Juanita says, “We are rapidly expanding our reach into the Nordic region and we’re advancing toward FDA approval in the US. To date, there have been more than 500 RefluxStop™ procedures carried out in Europe and adoption is moving quickly. That said, our biggest challenge right now is disease awareness. So many patients don’t know that a surgical option exists for them and they’re not aware of the long-term side effects of taking drugs to treat the issue. To add to that, many physicians don’t know about RefluxStop™ yet.” Most Innovative MedTech Company 2023 - Central Europe Jul23198 The company also has a large product pipeline which includes a portfolio of more than 1,000 patent cases and over 300 inventions. Notably, Implantica is working on two major breakthroughs: e-InVivo™, a sensor implant that collects data from inside the body, is set to disrupt the expanding e-health market. Designed to track a wealth of health parameters, e-InVivo™ provides diagnostic information and controls treatment from inside the body. The company is also developing a wireless energising platform for the next generation of implants. The platform will power and recharge remote-controlled implants in situ using wireless technology. For the remainder of 2023 and into 2024, Implantica’s primary focus is on growing market access for RefluxStop™ across Europe and North America. This includes the launch of a new patient website and app. To find out more, please visit the Implantica website. Contact: Juanita Eberhart Company: Implantica Trading AG Web Address: https://www.implantica.com/
RkJQdWJsaXNoZXIy MTUyMDQwMA==